Efficacy and Safety Study of Prucalopride for the Treatment of Chronic Constipation

This study has been completed.
Sponsor:
Information provided by:
Movetis
ClinicalTrials.gov Identifier:
NCT00617513
First received: February 6, 2008
Last updated: May 28, 2008
Last verified: February 2008
  Purpose

The purpose of this study is to determine which dose of prucalopride is safe and effective in patients with chronic idiopathic constipation.

Hypothesis:

Prucalopride 1 and 2 mg are safe and effective for the treatment of chronic idiopathic constipation whereas 0,5 mg is a suboptimal dose.


Condition Intervention Phase
Constipation
Drug: Prucalopride
Other: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind Placebo-Controlled Dose-Finding Trial to Evaluate the Efficacy and Safety of R093877 in Patients With Chronic Idiopathic Constipation

Resource links provided by NLM:


Further study details as provided by Movetis:

Primary Outcome Measures:
  • Evaluation of the efficacy of prucalopride and to compare the effects of 0.5 mg, 1 mg or 2 mg of R093877 versus placebo [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evaluation of the effects of R093877 on symptoms associated with idiopathic constipation [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Enrollment: 174
Study Start Date: March 1995
Study Completion Date: March 1996
Primary Completion Date: March 1996 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Drug: Prucalopride
0.5 mg once daily
Other Name: Resolor
Active Comparator: 2 Drug: Prucalopride
1 mg o.d.
Other Name: Resolor
Active Comparator: 3 Drug: Prucalopride
2 mg o.d.
Other Name: Resolor
Placebo Comparator: 4 Other: Placebo
o.d.

Detailed Description:

This is a phase II trial with a parallel-group design, consisting of a drug-free run-in phase (phase 1), followed by a placebo controlled double-blind phase (phase 2). Patients will receive either R093877 0.5 mg o.d., 1 mg o.d. or 2 mg o.d. or placebo for a period of 4 weeks.

Phase 1 is a run-in period of 4 weeks duration, during which the bowel habit is documented and the existence of constipation confirmed. At the start of this period all existing laxative medication is withdrawn but patients will be instructed not to change their dietary habits, in particular their fibre intake during the trial. Patients will enter the double-blind phase if constipation has been shown to be present during the run-in period.

If the definition of constipation was not met during the 4 weeks of the run-in period, double-blind treatment will not be started.

Phase 2 is a double-blind, randomized, placebo-controlled phase, in which patients will be treated for 4 weeks with either 0.5 mg, 1 mg or 2 mg of R093877 or placebo given once daily (one capsule is taken before breakfast).

Patients admitted to the double blind treatment period will be randomly allocated to one of the 4 treatment arms.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age between 18-70 years.
  • History of constipation i.e., the patient reported the occurrence of TWO OR MORE of the following criteria for at least 6 months before the selection visit :

    1. two or fewer spontaneous* bowel movements in a week.
    2. lumpy (scyballae) and/or hard stools at least a quarter of the stools.
    3. sensation of incomplete evacuation following at least a quarter of the stools.
    4. straining at defaecation at least a quarter of the time. *A bowel movement was considered spontaneous if it was not preceded by the intake of a laxative agent within a period of 12 hours. An amendment was made changing this period to 24 hours. Moreover, the amendment stated: "Patients who never opened their bowels spontaneously would be considered constipated and eligible to enter the double-blind phase of the trial, whether or not the above mentioned criteria were met for laxativa/enemas induced stools".
  • Constipation causing disability; the patient's occupational, social and recreational activities were governed by his/her constipation and efforts to attain relief.
  • Normal electromyographic inhibition pattern of the external anal sphincter during straining (clinical and/or electromyographic and/or manometric evidence is acceptable).
  • Absence of organic abnormalities of the colon on barium enema or on total colonoscopic examination. This criterion was amended to: "If complaints of constipation were of recent onset,i.e., had been present for 6 months to 1 year, results of a colonoscopic examination performed within the last 12 months were needed. If complaints of constipation had been present for more than one year, results of an endoscopic examination performed within the past three years were acceptable".
  • Poor results with laxative treatment and diet counselling.
  • Constipation of a functional, i.e., idiopathic nature.
  • Availability of the patient's written informed consent.
  • Patient available for follow-up during the trial period as determined in the protocol.

Exclusion Criteria:

  • Constipation thought to be drug-induced.
  • Presence of secondary causes of constipation, for instance: endocrine disorders, metabolic disorders, neurologic disorders.
  • Congenital megacolon/megarectum.
  • History of previous abdominal surgery other than hysterectomy, surgery for Meckel's diverticle,appendicectomy, cholecystectomy, inguinal repair, splenectomy, nephrectomy or fundoplication.
  • Known or suspected organic disorders of the large bowel, i.e., obstruction, carcinoma or inflammatory bowel disease.
  • Active proctological conditions which were thought to be responsible for constipation.
  • Evidence of a non-relaxing pelvic floor ("anismus") as the main cause of constipation.
  • Clinically significant ECG abnormalities.
  • Known illnesses or conditions which might interfere in any way with the adequate assessment of the drug under study, such as severe cardiovascular or lung disease, neurologic or psychiatric disorders, alcoholism, cancer or AIDS.
  • Impaired renal function
  • Presence of a serum amylase-, a serum glutamic-oxaloacetic transaminase (SGOT) or a serum glutamic-pyruvic transaminase (SGPT) concentration of > 2 times the upper limit of normal.
  • Clinically significant abnormalities of blood chemistry, haematology or urinalysis at selection.
  • Pregnancy or wish to become pregnant during the course of the study. - Breast feeding.
  • Investigational drug received in the 30 days preceding the trial.
  • Known use of street drugs e.g., marijuana, cocaine etc.
  • Unability or unwillingness to return for required follow-up visits.
  • Reliability and physical state preventing proper evaluation of a drug trial.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00617513

Sponsors and Collaborators
Movetis
Investigators
Principal Investigator: Marc Van Outryve, MD Jan Palfijn Hospital
  More Information

No publications provided

Responsible Party: Renate Specht Gryp, Movetis
ClinicalTrials.gov Identifier: NCT00617513     History of Changes
Other Study ID Numbers: PRU-INT-1
Study First Received: February 6, 2008
Last Updated: May 28, 2008
Health Authority: Belgium: Institutional Review Board

Additional relevant MeSH terms:
Constipation
Signs and Symptoms, Digestive
Signs and Symptoms

ClinicalTrials.gov processed this record on April 16, 2014